Profiling the entire cancer genome identifies new subgroups of blood cancer

The University of Oxford has led the largest and most comprehensive analysis of the entire genomic landscape of the commonest type of blood cancer called chronic lymphocytic leukaemia (CLL) as part of the UK's 100,000 Genomes Project. This work defines five genomic subgroups of CLL and associates these with clinical outcomes, and these subgroups provide a better estimation of patient prognosis than achieved by previous single gene analyses, allowing more tailored patient care. A collaborative study led by the University of Oxford as part of the UK's 100,000 Genomes Project, published in Nature Genetics , has defined five new subgroups of the most common type of blood cancer, chronic lymphocytic leukaemia (CLL) and associated these with clinical outcomes. This new method for risk stratifying patients could lead to more personalised patient care. This is the first study to analyse all the relevant changes in DNA across the entire cancer genome, rather than targeted regions, to classify patients with cancer and link these subgroups to clinical outcomes. Professor Anna Schuh  of Oxford's  Department of Oncology , who led the study, said: 'We know that cancer is fundamentally a disease caused by changes in DNA that are acquired over the lifetime of an individual. The lab tools we currently use to predict whether or not a patient is likely to respond to a given therapy usually focus on single abnormalities in the cancer DNA and do not accurately predict the patient's clinical outcome.